American Journal of Transplantation最新文献

Archetypal Analysis of Deceased Donor Kidneys: A Molecular Approach for Posttransplant Outcomes. 已故供体肾脏的原型分析：移植后结果的分子方法。

IF 8.2 2区医学

American Journal of Transplantation Pub Date : 2025-10-04 DOI: 10.1016/j.ajt.2025.09.024

Petra Hruba, Jiri Klema, Eva Girmanova, Petra Mrazova, Lucie Capkova, Katarina Jakubov, Jiri Fronek, Roman Keleman, Ludek Voska, Martina Mackova, Konrad Famulski, Philip F Halloran, Ondrej Viklicky

{"title":"Archetypal Analysis of Deceased Donor Kidneys: A Molecular Approach for Posttransplant Outcomes.","authors":"Petra Hruba, Jiri Klema, Eva Girmanova, Petra Mrazova, Lucie Capkova, Katarina Jakubov, Jiri Fronek, Roman Keleman, Ludek Voska, Martina Mackova, Konrad Famulski, Philip F Halloran, Ondrej Viklicky","doi":"10.1016/j.ajt.2025.09.024","DOIUrl":"https://doi.org/10.1016/j.ajt.2025.09.024","url":null,"abstract":"<p><p>Donor kidney tissue based transcriptomics may represent new dimension for prediction of kidney transplant outcomes. In this prospective, single-center study, 276 kidneys from 174 deceased brain-death donors were assessed by microarrays to identify phenotypes of procurement biopsies. Molecular classifiers (extreme gradient boosting, logistic and Poisson regression) with 10-fold cross-validation were employed to categorize donors based on clinical variables (age, BMI, hypertension, ECD kidney) and histological scores (vascular fibrous intimal thickening, interstitial fibrosis, tubular atrophy, arteriolar hyaline thickening). Archetypal analysis and linear mixed model were applied to determine molecular phenotypes and their association with posttransplant 1-year eGFR in 234 donor kidneys. Three molecular archetypes were identified. The \"ideal\" archetype (median donor age 42 years, low KDRI, minimal chronic histological changes) was associated with the highest 1-year eGFR, while the \"marginal\" archetype (68 years, extensive chronic changes, high KDRI) with the lowest one. The \"intermediate\" archetype yielded better 1-year eGFR despite donor profiles similar to the marginal group. While KDRI predicted 1-year eGFR, adding molecular archetypes improved model performance (AIC 80.0 vs. 83.7;p<0.05). External validation in an independent dataset (n=174, GSE147451) confirmed predictive value of the model. Molecular profiling of procurement biopsies may help to identify donor kidneys with higher posttransplant eGFR.</p>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145237548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025-26 Influenza Season. 用疫苗预防和控制季节性流感：免疫实践咨询委员会的建议——美国，2025-26年流感季节

IF 8.2 2区医学

American Journal of Transplantation Pub Date : 2025-10-04 DOI: 10.1016/j.ajt.2025.10.002

Marcus R Pereira

引用次数: 0

Islet cell alloautotransplantation 12 years after simultaneous pancreas-kidney transplantation 胰岛细胞移植：SPK移植后12年。

IF 8.2 2区医学

American Journal of Transplantation Pub Date : 2025-10-01 DOI: 10.1016/j.ajt.2025.05.034

Ahmer Hameed , Katie Connor , Alan Timpson , Lora Irvine , Sharon Zahra , Caroline Fattah , Kirsty Duncan , John Plevris , Chris Fraser , Avinash Sewpaul , Shareen Forbes , John Casey , Andrew Sutherland

{"title":"Islet cell alloautotransplantation 12 years after simultaneous pancreas-kidney transplantation","authors":"Ahmer Hameed , Katie Connor , Alan Timpson , Lora Irvine , Sharon Zahra , Caroline Fattah , Kirsty Duncan , John Plevris , Chris Fraser , Avinash Sewpaul , Shareen Forbes , John Casey , Andrew Sutherland","doi":"10.1016/j.ajt.2025.05.034","DOIUrl":"10.1016/j.ajt.2025.05.034","url":null,"abstract":"<div><div><span>Late enteric bleeding in the setting of simultaneous pancreas-kidney transplantation is an uncommon but perhaps underrecognized complication that can result in major morbidity. There are significant challenges both in the diagnosis and management of this complication, and in certain circumstances, graft pancreatectomy<span> of an otherwise functioning graft may be required. Here we present the case of a 49-year-old simultaneous pancreas-kidney transplant recipient who presented 12 years after transplant with recurrent life-threatening enteric bleeding that required a graft pancreatectomy. After pancreatectomy, islets were isolated from the allograft—190 000 islet equivalents with 90% viability and 27% purity. The islets were transplanted back into the recipient percutaneously via the portal vein<span>, with detectable C-peptide 6 weeks after procedure and no hypoglycemic unawareness. A second allogeneic islet cell transplant was subsequently performed two months later, with the patient’s latest C-peptide of 430 pmol/L, having maintained good renal function. Alloautotransplantation is a potential treatment option for patients that require graft pancreatectomy and has the advantage of preserving some beta-cell function while not necessitating additional </span></span></span>immunosuppression.</div></div>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"25 10","pages":"Pages 2244-2248"},"PeriodicalIF":8.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144197836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Practices in the management of kidney transplant candidates and recipients with obesity: A survey of United States transplant programs 肥胖患者肾移植候选人和受者的管理实践：美国移植项目调查

IF 8.2 2区医学

American Journal of Transplantation Pub Date : 2025-10-01 DOI: 10.1016/j.ajt.2025.05.033

Chethan M. Puttarajappa , Megan Urbanski , M. Kazem Fallahzadeh , Pooja Budhiraja , Vasanthi Balaraman , W. Scott Butsch , Harry Morford , Prince M. Anand , Kenneth J. Woodside , Babak J. Orandi

{"title":"Practices in the management of kidney transplant candidates and recipients with obesity: A survey of United States transplant programs","authors":"Chethan M. Puttarajappa , Megan Urbanski , M. Kazem Fallahzadeh , Pooja Budhiraja , Vasanthi Balaraman , W. Scott Butsch , Harry Morford , Prince M. Anand , Kenneth J. Woodside , Babak J. Orandi","doi":"10.1016/j.ajt.2025.05.033","DOIUrl":"10.1016/j.ajt.2025.05.033","url":null,"abstract":"<div><div><span><span>There is growing kidney transplant program-level interest in addressing obesity. The American Society of </span>Transplantation Kidney Pancreas<span><span><span> Community of Practice Obesity Work Group surveyed US programs to characterize evaluation, listing, and weight management practices. A web-based survey was administered to professionals involved in kidney transplant care (transplant nephrologists/surgeons/coordinators/dietitians, endocrinologists, </span>bariatric surgeons, and obesity medicine specialists) from May 2024 to September 2024. The 275 respondents from 113 programs represented 70.7% of the US transplant volume. A </span>body mass index (BMI) cutoff—commonly 40 kg/m</span></span><sup>2</sup>—is used for evaluation/listing at 72.5%/74.3% of programs. For recipients, BMI 40 kg/m<sup>2</sup><span><span> was the most common threshold for referral for medical and surgical weight loss. Most (73.4%) programs have weight management programs within their institution; 19.4% have a program integrated into their transplant program. One of the most common reasons for not referring for weight management was a preference that primary care providers/general nephrologists manage this, particularly pretransplant. Of programs, 27.6% offer robotic </span>kidney transplantation; 38.5% offer it only to patients above a BMI threshold (32-40 kg/m</span><sup>2</sup><span>). Obesity management is heterogeneous. Most use a BMI cutoff—typically 40 kg/m</span><sup>2</sup>—for evaluation and listing. These data provide the most comprehensive and contemporary overview of practices at US programs.</div></div>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"25 10","pages":"Pages 2194-2205"},"PeriodicalIF":8.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144207252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of delayed graft function with cardiovascular outcomes in kidney transplant recipients 肾移植受者移植功能延迟与心血管预后的关系

IF 8.2 2区医学

American Journal of Transplantation Pub Date : 2025-10-01 DOI: 10.1016/j.ajt.2025.05.036

Thomas Beaudrey , Estelle Aymes , Olivier Thaunat , Dimitri Bedo , Christophe Masset , Vincent Pernin , Philippe Gatault , Marc Ladrière , Marie-Pascale Morin , Coralie Poulain , Antoine Thierry , Dominique Bertrand , Valérie Chatelet , Laetitia Albano , Yannick Le Meur , Anne Elisabeth Heng , Charlotte Boud’Hors , Jean Philippe Rerolle , Guillaume Claisse , Sophie Caillard , Nans Florens

{"title":"Association of delayed graft function with cardiovascular outcomes in kidney transplant recipients","authors":"Thomas Beaudrey , Estelle Aymes , Olivier Thaunat , Dimitri Bedo , Christophe Masset , Vincent Pernin , Philippe Gatault , Marc Ladrière , Marie-Pascale Morin , Coralie Poulain , Antoine Thierry , Dominique Bertrand , Valérie Chatelet , Laetitia Albano , Yannick Le Meur , Anne Elisabeth Heng , Charlotte Boud’Hors , Jean Philippe Rerolle , Guillaume Claisse , Sophie Caillard , Nans Florens","doi":"10.1016/j.ajt.2025.05.036","DOIUrl":"10.1016/j.ajt.2025.05.036","url":null,"abstract":"<div><div><span><span>Cardiovascular disease remains a major cause of morbidity and mortality in kidney transplant<span> recipients. This multicenter cohort study examined the association between </span></span>delayed graft function<span> (DGF) and major adverse cardiovascular events (MACEs) in a cohort of 18 149 kidney transplant recipients from 17 French hospitals, transplanted between 2008 and 2022. The primary outcome measured was the incidence of MACEs, including cardiovascular death, coronary artery disease<span><span>, heart failure, and stroke, with secondary outcomes of graft failure and noncardiovascular death. Among the cohort, 4182 (23.0%) experienced DGF, which was associated with a significantly increased risk of MACEs (hazard ratio: 1.24, 95% confidence interval: 1.10-1.40), particularly </span>coronary artery disease, heart failure, and cardiovascular death, but not stroke. The association of DGF with an increased MACE incidence remained consistent over time (</span></span></span><em>P</em>-interaction = .19) and intensified with greater DGF severity, as measured by the number of dialysis sessions required after transplantation (<em>P</em>-trend = .01). Graft function did not significantly mediate the association between DGF and MACEs (<em>P</em><span> = .62). These findings suggest that the renal lesions resulting from DGF may mediate cardiovascular risk, highlighting the need for optimized prevention and treatment strategies to improve patient outcomes.</span></div></div>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"25 10","pages":"Pages 2182-2193"},"PeriodicalIF":8.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144245421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emphysematous graft pancreatitis 20 years after transplant 肺气肿性移植物胰腺炎移植后20年

IF 8.2 2区医学

American Journal of Transplantation Pub Date : 2025-10-01 DOI: 10.1016/j.ajt.2025.05.016

Alban Longchamp , Carlos A. Portales Castillo , Sarah P. Hammond , Nahel Elias

引用次数: 0

Soluble CD95L is a prognostic marker in central nervous system posttransplant lymphoproliferative disorders 可溶性CD95L是中枢神经系统移植后淋巴增生性疾病的预后标志物。

IF 8.2 2区医学

American Journal of Transplantation Pub Date : 2025-10-01 DOI: 10.1016/j.ajt.2025.05.010

Antoine Tichadou , Eden Lebrault , Assia Samri , Marine Baron , Cécilia Nakid-Cordero , David Lavergne , Véronique Morin , Oulfata Mze , Noureddine Balegroune , Xiaozhen Liang , Sylvain Choquet , Amélie Guihot , Patrick Legembre , Murielle Roussel , K-VIROGREF Study Group

{"title":"Soluble CD95L is a prognostic marker in central nervous system posttransplant lymphoproliferative disorders","authors":"Antoine Tichadou , Eden Lebrault , Assia Samri , Marine Baron , Cécilia Nakid-Cordero , David Lavergne , Véronique Morin , Oulfata Mze , Noureddine Balegroune , Xiaozhen Liang , Sylvain Choquet , Amélie Guihot , Patrick Legembre , Murielle Roussel , K-VIROGREF Study Group","doi":"10.1016/j.ajt.2025.05.010","DOIUrl":"10.1016/j.ajt.2025.05.010","url":null,"abstract":"<div><div>CD95L is a transmembrane cytokine mainly expressed by activated T and natural killer cells to contract the immune response through cell-cell contact. Conversely, after cleavage by metalloproteases, this ligand releases a soluble CD95L (sCD95L) that stimulates the immune response and its antitumor activity. In posttransplant lymphoproliferative disorders (PTLDs), we hypothesized that the concentration of sCD95L could exert a biological function and affect clinical outcomes by modulating the immune response. Using the K-VIROGREF biobank, we quantified sCD95L in 163 patients with PTLD, 16 transplant controls, and 28 healthy donors. Transplant recipients had higher plasma levels of sCD95L than healthy donors. More interestingly, patients with PTLD and high concentration of sCD95L had better clinical outcomes than patients with lower concentration, particularly those with central nervous system (CNS) involvement, who are known to have poor survival. At the cellular level, only natural killer and natural killer T-like cell fractions were reduced in the blood of patients with CNS-PTLD and high concentration of sCD95L, suggesting that sCD95L may either promote the trafficking of these cells within tumors or modulate their differentiation/survival. In conclusion, we showed in this exploratory analysis that plasma concentration of sCD95L might be a prognostic marker in patients with PTLD, particularly in those with CNS involvement.</div></div>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"25 10","pages":"Pages 2127-2141"},"PeriodicalIF":8.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144065585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pretransplant natural antibody levels identify a subset of deceased donor kidney transplant recipients that benefit from infliximab induction 移植前天然抗体水平确定了从英夫利昔单抗诱导中受益的已故供体肾移植受者的子集。

IF 8.2 2区医学

American Journal of Transplantation Pub Date : 2025-10-01 DOI: 10.1016/j.ajt.2025.06.003

Vojtech Petr , Filip Tichanek , Samuel L. Liu , Felix Poppelaars , Brandon Renner , Jennifer Laskowski , Shrey Purohit , Ming Zhao , Diana Jalal , Peter S. Heeger , Joshua M. Thurman

{"title":"Pretransplant natural antibody levels identify a subset of deceased donor kidney transplant recipients that benefit from infliximab induction","authors":"Vojtech Petr , Filip Tichanek , Samuel L. Liu , Felix Poppelaars , Brandon Renner , Jennifer Laskowski , Shrey Purohit , Ming Zhao , Diana Jalal , Peter S. Heeger , Joshua M. Thurman","doi":"10.1016/j.ajt.2025.06.003","DOIUrl":"10.1016/j.ajt.2025.06.003","url":null,"abstract":"<div><div>Targeting peritransplant inflammation via tumor necrosis factor alpha<span><span><span> blockade failed to improve kidney transplantation outcomes in the CTOT-19 trial that tested </span>infliximab<span> (IFX) induction. As natural antibodies (nAbs) to cardiolipin and </span></span>phosphatidylethanolamine<span><span><span> promote graft injury, we hypothesized that CTOT-19 outcomes were confounded by nAb levels. Pretransplant plasma anticardiolipin (aCL) and antiphosphatidylethanolamine (aPE) immunoglobulin M/immunoglobulin G (IgM/IgG) were measured in 177 CTOT-19 subjects and analyzed in relation to </span>delayed graft function (DGF), 2-year estimated </span>glomerular filtration rate<span>, and infection. Bayesian modeling with a nonlinear treatment–antibody interaction estimated that the IFX effects depend on aCL IgG/IgM and aPE IgG. In patients with low aCL IgG, IFX reduces DGF risk (odds ration [OR] at the fifth percentile, 0.13; 95% credible interval (95% CrI), 0.03-0.49) but increases risk at the 95th percentile of aCL IgG levels (OR, 6.24; 95% CrI, 1.38-30.32). In patients with aCL IgG below the median, IFX has a positive indirect effect on the estimated glomerular filtration rate via reducing DGF rates. Finally, IFX increases infection risk in patients with low aPE IgG (OR at the fifth percentile, 3.12; 95% CrI, 1.11-9.08). This analysis identifies a subset of CTOT-19 subjects who likely benefit from IFX and suggests pretransplant nAb levels may serve as biomarkers for response to early posttransplant anti-inflammatory therapies.</span></span></span></div></div>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"25 10","pages":"Pages 2173-2181"},"PeriodicalIF":8.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144245423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to “Pancreas transplant outcomes in patients with human immunodeficiency virus infection” [American Journal of Transplantation 25 (2025) 836–847] “人类免疫缺陷病毒感染患者的胰腺移植结果”的勘误表[美国移植杂志25 (2025)836-847]

IF 8.2 2区医学

American Journal of Transplantation Pub Date : 2025-10-01 DOI: 10.1016/j.ajt.2025.06.002

Rashmi R. Bharadwaj , Gabriel Orozco , Xiaonan Mei , Hanine El-Haddad , Roberto Gedaly , Meera Gupta

引用次数: 0

Reply to Malik and Patel, managing recurrence after liver transplant for colorectal liver metastasis 回复马利克和帕特尔。

IF 8.2 2区医学

American Journal of Transplantation Pub Date : 2025-10-01 DOI: 10.1016/j.ajt.2025.06.031

Matthew M. Byrne , Koji Tomiyama , Roberto Hernandez-Alejandro

引用次数: 0